NanO2TM Combined With Radiation and Temozolomide in Glioblastoma (RESTORE)

I'm Interested!

Please call
1-800-641-2422

A phase 2 double-blind, RandomizEd, prospective, placebo controlled STudy of NanO2 TM combined with Radiation and temozolomide in patients with newly-diagnosed glioblastoma multiformE: RESTORE

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Brain and Nervous System

Study Purpose

This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.

Principal Investigator
Herbert Newton MD

Department/Division
Cancer (Brain and Central Nervous System)

Locations

UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: STUDY20240082
StudyID: NVOX1323
ClinicalTrials.gov: NCT03862430

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422